
Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance
Designer Brands (NYSE:DBI) reported a slight expansion in its first-quarter top-line revenue, driven by strong growth within its wholesale division that helped offset softening demand across its core brick-and-mortar storefront network.
The Columbus-based footwear and accessories retailer recorded net sales of $696.4 million for the first quarter of fiscal 2026, representing a 1.4% improvement compared to the same period a year earlier.
The modest revenue growth occurred despite a 1.1% decline in total comparable store sales, demonstrating a divergence between the company's direct-to-consumer retail traffic and its commercial brand distribution channels.
Operational profitability showed notable resilience during the three-month period.
Designer Brands reported that its gross profit climbed to $315.3 million, with its gross margin expanding by 240 basis points to reach 45.3%.
The margin improvement suggests that promotional discipline and careful inventory clearance mitigated broader inflationary headwinds across the apparel supply chain.
For the quarter, the company posted reported net income of $1.2 million, or $0.02 per diluted share.
On an adjusted basis, diluted earnings per share landed at $0.07.
The primary catalyst for the period's performance was the company's proprietary manufacturing and design engine.
Net sales within the Brand Portfolio segment—which manages its national and owned footwear labels—surged 19.4% year-over-year, offsetting consumer headwinds within its retail stores.
Looking forward, corporate leadership expressed confidence in its operational trajectory by holding its previous financial targets steady.
Designer Brands reaffirmed its full-year 2026 guidance, continuing to project full-year net sales performance to range between a 1% decline and a 1% increase.
The company also maintained its anticipated full-year diluted earnings per share guidance of $0.28 to $0.38, with management highlighting that it expects final results to track toward the higher end of that target range.
Frequently asked questions
More from United States
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab
DataMeds AI issues 630,000 shares in cancer partnership
CoinShares net income improves 27% to $39.6 million
newcleo revenue skyrockets 26% to €10 million in Q3